The Discounted Cash Flow (DCF) valuation of Intra-Cellular Therapies Inc (ITCI) is (488.03) USD. With the latest stock price at 131.87 USD, the upside of Intra-Cellular Therapies Inc based on DCF is -470.1%.
Based on the latest price of 131.87 USD and our DCF valuation, Intra-Cellular Therapies Inc (ITCI) is a sell. selling ITCI stocks now will result in a potential gain of 470.1%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 5.2% - 7.3% | 6.3% |
| Long-term Growth Rate | 3.0% - 4.9% | 4.0% |
| Fair Price | (4,443.76) - (258.94) | (488.03) |
| Upside | -3469.8% - -296.4% | -470.1% |